In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–789.
   Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Cao W, Chen H-D, Yu Y-W, Li N, Chen W-Q. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783. doi:10.1097/CM9.0000000000001474
   PubMed Web of Science ®Google Scholar
• Chapek MA, Martindale RG. Nutrition in cancer therapy: overview for the cancer patient. J Parenteral Enteral Nutr. 2021;10:21
   Google Scholar
• Pasha N, Turner NC. Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. Nature Cancer. 2021;4:1–13.
   Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi:10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009;4(11):e7695. doi:10.1371/journal.pone.0007695
   PubMed Web of Science ®Google Scholar
• Saneja A, Khare V, Alam N, Dubey RD, Gupta PN. Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opin Drug Deliv. 2014;11(1):121–138. doi:10.1517/17425247.2014.865014
   PubMed Web of Science ®Google Scholar
• Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002;38(13):1677–1684. doi:10.1016/S0959-8049(02)00151-X
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507. doi:10.2165/11531280-000000000-00000
   PubMed Web of Science ®Google Scholar
• Akindele AJ, Wani ZA, Sharma S, et al. In vitro and in vivo anticancer activity of root extracts of Sansevieria liberica Gerome and labroy (Agavaceae). Evidence-Based Compl Alternative Med. 2015;2015:560404. doi:10.1155/2015/560404
   PubMed Web of Science ®Google Scholar
• Haider MS, Ahmad T, Groll J, Scherf-Clavel O, Kroiss M, Luxenhofer R. The challenging pharmacokinetics of mitotane: an old drug in need of new packaging. Eur J Drug Metab Pharmacokinet. 2021;1–19.
   Web of Science ®Google Scholar
• Gallo JM, Vicini P, Orlansky A, et al. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clin Cancer Res. 2004;10(23):8048–8058. doi:10.1158/1078-0432.CCR-04-0822
   PubMed Web of Science ®Google Scholar
• White RE, Manitpisitkul P. Pharmacokinetic theory of cassette dosing in drug discovery screening. Drug Metab Dispos. 2001;29(7):957–966.
   PubMed Web of Science ®Google Scholar
• Graham M, Kaye S. New approaches in preclinical and clinical pharmacokinetics. Cancer Surv. 1993;17:27–49.
   PubMedGoogle Scholar
• Ogino M, Fujii T, Nakazawa Y, et al. Implications of Topoisomerase (TOP1 and TOP2α) expression in patients with breast cancer. In Vivo. 2020;34(6):3483–3487. doi:10.21873/invivo.12188
   PubMed Web of Science ®Google Scholar
• Bielawski K, Winnicka K, Bielawska A. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull. 2006;29(7):1493–1497. doi:10.1248/bpb.29.1493
   PubMed Web of Science ®Google Scholar
• Oksuzoglu E, Tekiner-Gulbas B, Alper S, et al. Some benzoxazoles and benzimidazoles as DNA topoisomerase I and II inhibitors. J Enzyme Inhib Med Chem. 2008;23(1):37–42. doi:10.1080/14756360701342516
   PubMed Web of Science ®Google Scholar
• Ahn B-Z, Baik K-U, Kweon G-R, Lim K, Hwang B-D. Acylshikonin analogs: synthesis and inhibition of DNA topoisomerase-I. J Med Chem. 1995;38(6):1044–1047. doi:10.1021/jm00006a025
   PubMed Web of Science ®Google Scholar
• Walker JV, Nitiss JL. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest. 2002;20(4):570–589. doi:10.1081/CNV-120002156
   PubMed Web of Science ®Google Scholar
• Solary E, Bertrand R, Pommier Y. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leuk Lymphoma. 1994;15(1–2):21–32. doi:10.3109/10428199409051674
   PubMed Web of Science ®Google Scholar
• Onishi Y, Azuma Y, Sato Y, Mizuno Y, Tadakuma T, Kizaki H. Topoisomerase inhibitors induce apoptosis in thymocytes. Biochim Biophys Acta. 1993;1175(2):147–154. doi:10.1016/0167-4889(93)90017-J
   PubMedGoogle Scholar
• Utsugi T, Mattern MR, Mirabelli CK, Hanna N. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res. 1990;50(9):2636–2640.
   PubMed Web of Science ®Google Scholar
• Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem. 1984;259(21):13560–13566. doi:10.1016/S0021-9258(18)90729-5
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260(27):14873–14878. doi:10.1016/S0021-9258(17)38654-4
   PubMed Web of Science ®Google Scholar
• Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4ʹ-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Nat Acad Sci. 1984;81(5):1361–1365. doi:10.1073/pnas.81.5.1361
   PubMed Web of Science ®Google Scholar
• Di X, Gennings C, Bear HD, et al. Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res Treat. 2010;124(2):349–360. doi:10.1007/s10549-010-0765-7
   PubMed Web of Science ®Google Scholar
• Masuda N, Matsui K, Negoro S, et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1998;16(10):3329–3334. doi:10.1200/JCO.1998.16.10.3329
   PubMed Web of Science ®Google Scholar
• Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol. 1996;14(1):257–267. doi:10.1200/JCO.1996.14.1.257
   PubMed Web of Science ®Google Scholar
• He S, Dong G, Wang Z, et al. Discovery of novel multiacting topoisomerase I/II and histone deacetylase inhibitors. ACS Med Chem Lett. 2015;6(3):239–243. doi:10.1021/ml500327q
   PubMed Web of Science ®Google Scholar
• Huang HS, Chen TC, Chen RH, et al. Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,11-dione homologues. Bioorg Med Chem. 2009;17(21):7418–7428. doi:10.1016/j.bmc.2009.09.033
   PubMed Web of Science ®Google Scholar
• Huang H-S, Chiou J-F, Fong Y, et al. Activation of human telomerase reverse transcriptase expression by some new symmetrical bis-substituted derivatives of the anthraquinone. J Med Chem. 2003;46(15):3300–3307. doi:10.1021/jm020492l
   PubMed Web of Science ®Google Scholar
• Huang H-S, Chiu H-F, Lee A-L, Guo C-L, Yuan C-L. Synthesis and structure–activity correlations of the cytotoxic bifunctional 1,4-diamidoanthraquinone derivatives. Bioorg Med Chem. 2004;12(23):6163–6170. doi:10.1016/j.bmc.2004.09.001
   PubMed Web of Science ®Google Scholar
• Shen C-J, Lin P-L, Lin H-C, Cheng Y-W, Huang H-S, Lee H. RV-59 suppresses cytoplasmic Nrf2-mediated 5-fluorouracil resistance and tumor growth in colorectal cancer. Am J Cancer Res. 2019;9(12):2789–2796.
   PubMed Web of Science ®Google Scholar
• Huang HS, Yu DS, Chen TC. Thiochromeno [2, 3-c] quinolin-12-one derivatives, preparation method and application thereof. Google Patents; 2015.
   Google Scholar
• Lawal B, Wang Y-C, Wu ATH, Huang H-S. Pro-oncogenic c-Met/EGFR, biomarker signatures of the tumor microenvironment are clinical and therapy response prognosticators in colorectal cancer, and therapeutic targets of 3-phenyl-2H-benzo[e][1,3]-oxazine-2,4(3H)-dione derivatives. Front Pharmacol. 2021;12:2300. doi:10.3389/fphar.2021.691234
   Web of Science ®Google Scholar
• Thurston DE, Pysz I. Chemistry and Pharmacology of Anticancer Drugs. CRC press; 2021.
   Google Scholar
• Chen T-C, Wu C-L, Lee -C-C, Chen C-L, Yu D-S, Huang H-S. Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents. Eur J Med Chem. 2015;103:615–627. doi:10.1016/j.ejmech.2014.09.050
   PubMed Web of Science ®Google Scholar
• Orellana EA, Kasinski AL. Sulforhodamine B (SRB) assay in cell culture to investigate cell proliferation. Bio-Protocol. 2016;6(21):e1984. doi:10.21769/BioProtoc.1984
   PubMedGoogle Scholar
• Chen T-C, Yu D-S, Chen S-J, et al. Design, synthesis and biological evaluation of tetracyclic azafluorenone derivatives with topoisomerase I inhibitory properties as potential anticancer agents. Arabian J Chem. 2019;12(8):4348–4364. doi:10.1016/j.arabjc.2016.06.014
   Web of Science ®Google Scholar
• Das P, Jain CK, Roychoudhury S, Majumder HK, Das S. Design synthesis and in vitro anticancer activity of a Cu(II) complex of carminic acid: a novel small molecule inhibitor of human DNA topoisomerase I and topoisomerase II. Chem Select. 2016;1(21):6623–6631. doi:10.1002/slct.201601152
   Google Scholar
• Doudka N, Giocanti M, Basso M, et al. Development and validation of a simple and rapid ultrahigh-performance liquid chromatography tandem spectrometry method for the quantification of hydroxychloroquine in plasma and blood samples in the emergency context of SARS-CoV-2 pandemic. Ther Drug Monit. 2021;43(4):570. doi:10.1097/FTD.0000000000000836
   PubMed Web of Science ®Google Scholar
• Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Nat Acad Sci. 2011;108(5):1850–1855. doi:10.1073/pnas.1011379108
   PubMed Web of Science ®Google Scholar
• Rao CV, Reddy BS, Steele VE, et al. Nitric oxide–releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther. 2006;5(6):1530–1538. doi:10.1158/1535-7163.MCT-06-0061
   PubMed Web of Science ®Google Scholar
• Traphagen NA, Hosford SR, Jiang A, et al. High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer. Oncogene. 2021;40(19):3408–3421. doi:10.1038/s41388-021-01782-w
   PubMed Web of Science ®Google Scholar
• Marcus D, Hanwell DEC, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform. 2012;4:17.
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461.
   PubMed Web of Science ®Google Scholar
• Lawal B, Liu Y-L, Mokgautsi N, et al. Pharmacoinformatics and preclinical studies of NSC765690 and NSC765599, potential STAT3/CDK2/4/6 inhibitors with antitumor activities against NCI60 human tumor cell lines. Biomedicines. 2021;9(1):92. doi:10.3390/biomedicines9010092
   PubMed Web of Science ®Google Scholar
• Lawal B, Lee C-Y, Mokgautsi N, et al. mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 are druggable candidates for N-(2,4-difluorophenyl)-2′,4′-difluoro-4-hydroxybiphenyl-3-carboxamide (NSC765598), with consequent anticancer implications. Front Oncol. 2021;11:932. doi:10.3389/fonc.2021.656738
   Web of Science ®Google Scholar
• Wu S-Y, Lin K-C, Lawal B, Wu TH, Wu C-Z. MXD3 as an onco-immunological biomarker encompassing the tumor microenvironment, disease staging, prognoses, and therapeutic responses in multiple cancer types. Comput Struct Biotechnol J. 2021;19:4970–4983. doi:10.1016/j.csbj.2021.08.047
   PubMed Web of Science ®Google Scholar
• Chen J-H, Wu ATH, Lawal B, et al. Identification of cancer hub gene signatures associated with immune-suppressive tumor microenvironment and ovatodiolide as a potential cancer immunotherapeutic agent. Cancers. 2021;13(15):3847. doi:10.3390/cancers13153847
   PubMed Web of Science ®Google Scholar
• Visualizer DS. BIOVIA, Dassault systèmes, BIOVIA workbook, release 2020; BIOVIA pipeline pilot, release 2020. San Diego: Dassault Systèmes; 2020.
   Google Scholar
• Clausen DM, Guo J, Parise RA, et al. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther. 2010;335(3):715–727. doi:10.1124/jpet.110.170555
   PubMed Web of Science ®Google Scholar
• You F, Gao C. Topoisomerase inhibitors and targeted delivery in cancer therapy. Curr Top Med Chem. 2019;19(9):713–729. doi:10.2174/1568026619666190401112948
   PubMed Web of Science ®Google Scholar